EN | RU
EN | RU

Help Support

Back

Study to evaluate the safety and efficacy of Eptinezumab for the prevention of chronic migraine

Study to evaluate the safety and efficacy of Eptinezumab for the prevention of chronic migraine Study to evaluate the safety and efficacy of Eptinezumab for the prevention of chronic migraine
Study to evaluate the safety and efficacy of Eptinezumab for the prevention of chronic migraine Study to evaluate the safety and efficacy of Eptinezumab for the prevention of chronic migraine

What's new?

Clinicians may use intravenous injections of 100 mg or 300 mg eptinezumab to provide sustained migraine preventive help for complete 24 weeks.

From a recent study, it is demonstrated that 100 mg or 300 mg intravenous eptinezumab is safe and efficient for migraine prevention in adult patients suffering from chronic migraine.

In this study, patients were given up to two intravenous doses of eptinezumab or placebo break by 12 weeks. The daily migraine and headache endpoints were recorded by the patients. 

Table: Decrease in mean monthly migraine days


The migraine responder rates became better after a second dose, with more eptinezumab treated patients. The percentages of patients who became better on patient-reported results, increased after the second dose and were better with eptinezumab than with placebo at every time positions.

It is concluded that intravenous administration of eptinezumab provided safe and sustained migraine preventive effects.

Source:

The Journal of Headache and Pain

Article:

Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study

Authors:

Stephen Silberstein et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: